146 related articles for article (PubMed ID: 8319997)
41. An orally active inhibitor of renin.
Pals DT; Thaisrivongs S; Lawson JA; Kati WM; Turner SR; DeGraaf GL; Harris DW; Johnson GA
Hypertension; 1986 Dec; 8(12):1105-12. PubMed ID: 3539793
[TBL] [Abstract][Full Text] [Related]
42. Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs.
Clozel JP; Véniant M; Sprecher U; Fischli W
J Cardiovasc Pharmacol; 1995 Oct; 26(4):674-7. PubMed ID: 8569232
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular effects of a renin inhibitor in relation to posture in nonhuman primates.
Pals DT; DeGraaf GL; Kati WM; Lawson JA; Smith CW; Skala GF
Clin Exp Hypertens A; 1985; 7(1):105-21. PubMed ID: 2986882
[TBL] [Abstract][Full Text] [Related]
44. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
Neuberg GW; Kukin ML; Penn J; Medina N; Yushak M; Packer M
Am J Cardiol; 1991 Jan; 67(1):63-6. PubMed ID: 1986506
[TBL] [Abstract][Full Text] [Related]
45. Increased plasma renin during renin inhibition. Studies with a novel immunoassay.
Hofbauer KG; Wood JM; Gulati N; Heusser C; Ménard J
Hypertension; 1985; 7(3 Pt 2):I61-5. PubMed ID: 2987126
[TBL] [Abstract][Full Text] [Related]
46. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
47. Effects of renin inhibition in the conscious primate Macaca fascicularis.
Hui KY; Knight DR; Nussberger J; Hartley LH; Vatner SF; Haber E
Hypertension; 1989 Nov; 14(5):480-7. PubMed ID: 2680962
[TBL] [Abstract][Full Text] [Related]
48. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
[TBL] [Abstract][Full Text] [Related]
49. Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension?
van Paassen P; de Zeeuw D; Navis G; de Jong PE
Hypertension; 1996 Feb; 27(2):202-8. PubMed ID: 8567042
[TBL] [Abstract][Full Text] [Related]
50. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
51. Combined renin and converting enzyme inhibition in rats.
Mento PF; Holt WF; Murphy WR; Wilkes BM
Hypertension; 1989 Jun; 13(6 Pt 2):741-8. PubMed ID: 2661429
[TBL] [Abstract][Full Text] [Related]
52. Comparison of chronic inhibition of renin and converting enzyme in the marmoset.
Wood JM; Jobber RA; Baum HP; Hofbauer KG
Clin Exp Hypertens A; 1987; 9(2-3):337-43. PubMed ID: 3038392
[TBL] [Abstract][Full Text] [Related]
53. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
54. Comparison of different drug interference with the renin-angiotensin system.
Hofbauer KG; Fuhrer W; Heusser C; Wood JM
J Cardiovasc Pharmacol; 1985; 7 Suppl 4():S62-8. PubMed ID: 2412016
[TBL] [Abstract][Full Text] [Related]
55. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.
Brunner DB; Desponds G; Biollaz J; Keller I; Ferber F; Gavras H; Brunner HR; Schelling JL
Br J Clin Pharmacol; 1981 May; 11(5):461-7. PubMed ID: 6268131
[TBL] [Abstract][Full Text] [Related]
56. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys.
Lacour C; Roccon A; Cazaubon C; Segondy D; Nisato D
J Hypertens; 1993 Nov; 11(11):1187-94. PubMed ID: 8301099
[TBL] [Abstract][Full Text] [Related]
58. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition.
Kiowski W; Linder L; Kleinbloesem C; van Brummelen P; Bühler FR
Circulation; 1992 Jan; 85(1):1-8. PubMed ID: 1728438
[TBL] [Abstract][Full Text] [Related]
59. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.
Glassman HN; Kleinert HD; Boger RS; Moyse DM; Griffiths AN; Luther RR
J Cardiovasc Pharmacol; 1990; 16 Suppl 4():S76-81. PubMed ID: 1705633
[TBL] [Abstract][Full Text] [Related]
60. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients.
Weber C; Birnböck H; Leube J; Kobrin I; Kleinbloesem CH; Van Brummelen P
Br J Clin Pharmacol; 1993 Dec; 36(6):547-54. PubMed ID: 12959271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
